ERDERA Clinical Trial Call 2026 – Pre-announcement

1:1
Pre-announcement describing scope, eligibility and indicative timeline for the ERDERA Clinical Trial Call 2026, expected to open on 1 July 2026.

This pre-announcement outlines the upcoming ERDERA Clinical Trial Call 2026 (ECTC), expected to open on 1 July 2026, to support multinational, GCP-compliant Phase I, Phase I/II and Phase II interventional clinical trials in rare diseases.

It summarises priority areas, eligible applicants, eligible interventions (including small molecules, ATMPs and biologics), expected eligible countries and an indicative multi-stage application process, including an information webinar on 6 July 2026 (15:00–17:00 CEST).

blank

publication

You might also be interested in

July 24 @ 3:00 pm - 4:00 pm
This webinar will present a theoretical framework for situating ethics across research activities. The framework will then be brought to life through a relevant case study discussion, giving participants a concrete reference point for the episodes ahead.
This 2026 country report outlines the policy, research, care and support landscape for rare diseases in Poland.
Held in Riga on 9–10 June, the workshop brought National Mirror Group experts, researchers, clinicians and policymakers together to exchange practical lessons on how national rare disease registries can better support research and alignment across countries.
ERDERA (the European Rare Diseases Research Alliance) has opened its Clinical Trial Call to support multinational early-phase clinical trials in rare diseases. The call will fund studies designed to generate robust clinical evidence, strengthen regulatory readiness and make rare disease trials more feasible across countries.